Morpholino

MO3-vezf1b

ID

ZDB-MRPHLNO-200818-3

Name

MO3-vezf1b

Previous Names

None

Target

vezf1b (1)

Sequence

5' - CATTGGCCTGCTGGATGGAGAAAGA - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

Splice-blocking MO.

Genome Resources

None

Target Location

Genomic Features

No data available

Expression

Gene expression in Wild Types + MO3-vezf1b

No data available

Phenotype

Phenotype resulting from MO3-vezf1b

Phenotype	Fish	Figures
cardiac ventricle cardiac muscle cell decreased amount, abnormal	WT + MO3-vezf1b	Fig. 3 from Paavola et al., 2020
cardiac ventricle cardiac muscle cell decreased size, abnormal	WT + MO3-vezf1b	Fig. 3 from Paavola et al., 2020
heart decreased functionality, abnormal	WT + MO3-vezf1b	Fig. 4 from Paavola et al., 2020
heart contraction process quality, abnormal	WT + MO3-vezf1b	Fig. 4 from Paavola et al., 2020
pericardial cavity increased area, abnormal	WT + MO3-vezf1b	Fig. S1 from Paavola et al., 2020
pericardium edematous, abnormal	WT + MO3-vezf1b	Fig. S1 from Paavola et al., 2020
posterior cardinal vein decreased distance dorsal aorta, abnormal	WT + MO3-vezf1b	Fig. 2 from Paavola et al., 2020

Phenotype of all Fish created by or utilizing MO3-vezf1b

Phenotype	Fish	Conditions	Figures
cardiac ventricle cardiac muscle cell decreased size, abnormal	WT + MO3-vezf1b	standard conditions	Fig. 3 from Paavola et al., 2020
posterior cardinal vein decreased distance dorsal aorta, abnormal	WT + MO3-vezf1b	chemical treatment: isoprenaline	Fig. 2 from Paavola et al., 2020
posterior cardinal vein decreased distance dorsal aorta, abnormal	WT + MO3-vezf1b	standard conditions	Fig. 2 from Paavola et al., 2020
heart decreased functionality, abnormal	WT + MO3-vezf1b	standard conditions	Fig. 4 from Paavola et al., 2020
heart contraction process quality, abnormal	WT + MO3-vezf1b	standard conditions	Fig. 4 from Paavola et al., 2020
cardiac ventricle cardiac muscle cell size, ameliorated	WT + MO3-vezf1b	chemical treatment: isoprenaline	Fig. 3 from Paavola et al., 2020
heart contraction process quality, abnormal	WT + MO3-vezf1b	chemical treatment: isoprenaline	Fig. 4 from Paavola et al., 2020
pericardial cavity increased area, abnormal	WT + MO3-vezf1b	standard conditions	Fig. S1 from Paavola et al., 2020
pericardium edematous, exacerbated	WT + MO3-vezf1b	chemical treatment: isoprenaline	Fig. S1 from Paavola et al., 2020
intersegmental vessel increased distance intersegmental vessel, abnormal	WT + MO3-vezf1b	chemical treatment: isoprenaline	Fig. 2 from Paavola et al., 2020
pericardium edematous, abnormal	WT + MO3-vezf1b	standard conditions	Fig. S1 from Paavola et al., 2020
cardiac ventricle cardiac muscle cell amount, ameliorated	WT + MO3-vezf1b	chemical treatment: isoprenaline	Fig. 3 from Paavola et al., 2020
cardiac ventricle cardiac muscle cell decreased amount, abnormal	WT + MO3-vezf1b	standard conditions	Fig. 3 from Paavola et al., 2020
pericardial cavity increased area, exacerbated	WT + MO3-vezf1b	chemical treatment: isoprenaline	Fig. S1 from Paavola et al., 2020

Citations